Schenk Dale B, Seubert Peter, Grundman Michael, Black Ron
Elan Pharmaceuticals, San Francisco, CA 94080, USA.
Neurodegener Dis. 2005;2(5):255-60. doi: 10.1159/000090365.
Amyloid-beta (A beta) immunotherapy for treatment of Alzheimer's disease (AD) was first described in 1999 and has been very informative regarding the role of A beta in AD. Through the efforts of many laboratories we now know that it is possible to reduce amyloid burden and many related AD pathologies in numerous animal models of the disease. Furthermore, initial clinical testing with AN1792, composed of A beta(1-42 )and an adjuvant, has yielded very important insights into both the clinical potential of the approach and the impact of A beta peptide on the disease. A brief review of our current understanding of A beta immunotherapy is described. These findings have led to newer alternative A beta immunotherapy approaches that include both active and passive approaches that are currently in clinical testing in both the USA and Europe.
用于治疗阿尔茨海默病（AD）的β-淀粉样蛋白（Aβ）免疫疗法于1999年首次被描述，它为了解Aβ在AD中的作用提供了很多信息。通过众多实验室的努力，我们现在知道，在该疾病的众多动物模型中，降低淀粉样蛋白负荷以及许多相关的AD病理特征是可能的。此外，由Aβ（1-42）和一种佐剂组成的AN1792的初步临床试验，为该方法的临床潜力以及Aβ肽对疾病的影响提供了非常重要的见解。本文简要回顾了我们目前对Aβ免疫疗法的理解。这些发现催生了更新的替代性Aβ免疫疗法，包括主动和被动方法，目前正在美国和欧洲进行临床试验。
